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Abstract
Migraine remains one of the biggest clinical case to be solved among the non-communicable diseases, second to
low back pain for disability caused as reported by the Global Burden of Disease Study 2016. Despite this, its
genetics roots are still unknown. Its evolution in chronic forms hits 2–4% of the population and causes a form so
far defined Medication Overuse Headache (MOH), whose pathophysiological basis have not been explained by
many dedicated studies. The Global Burden of Disease Study 2016 has not recognized MOH as independent entity,
but as a sequela of Chronic Migraine. This concept, already reported in previous studies, has been confirmed by the
efficacy of OnabotulinumtoxinA in Chronic Migraine independently from the presence of MOH. The consistency of
the current definitions of both Medication Overuse Headache and Chronic Migraine itself might be re-read on the
basis of new evidences.
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Medication overuse headache: Chasing roots and
Borders
Medication Overuse Headache (MOH) is an underesti-
mated social plague, that has always struggled to find re-
search funds for epidemiological studies on large clinical
records [1–3], probably due to non-scientific scotomata.
The International Classification of Headache Disorders
has interpreted MOH in an improper way through the
years, and this has led to many clarifications and criti-
cisms [4, 5]. In fact, it is considered a headache second-
ary to the pharmacological abuse itself, without any
consideration of the fact that MOH roots on Chronic
Migraine (CM) [6]. Therefore, it must be considered as a
complication of CM only. Rehabilitation from drug
abuse, in whichever modality it is carried out, produces
de facto a return to CM [7]. The same therapies applied
today to CM are in fact efficacious with or without the
presence of MOH, and an artificial distinction of a clas-
sification does not distinguish their efficacy [8–10].
Furthermore, we know that when migraineurs, whose
genetic base remains yet undefined, despite the scientific
efforts [11], develop CM plus Medication Overuse (MO)
do not show univocal genetic patterns. Studies in this
sector are at least jeopardized, and results correlate on
various polymorphisms not always assonant, if we con-
sider their action as drivers on possible physio-
pathological patterns [12–15]. Many refined functional
neuroimaging studies applied to MOH undergo the
same jeopardized criteria [16–18].
So, if we look for a generator of CM complication in
CM plus MO we will have to look at the comorbidities
spectrum, like depression, visceral pain, fibromyalgia,
orofacial pain, temporo-mandibular disorders, myofas-
cial trigger points that act on migraine incrementing its
disability and an uncontrolled multiple need of analge-
sics [19]. This additional use disadvantages only
migraine, since the patient with other osteoarticular
pathologies who frequently uses analgesics and antimi-
graine drugs, if not migraneurs, will never develop any
MO(H), ever. [19].
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Changing the classification of MOH as sequela of CM
MOH doesn’t have a genetic predisposition, then.
Contradictory and varied studies did not lead to com-
mon denominator for a simple reason: MOH is not an
entity independently classifiable, as the International
Classification of Headache Disorders leads us to thin. It
is a simple sequela, a complication of CM, as we
affirmed in 2011 [4, 5] and now validated in the recent
Global Burden of Diseases 2016 (GBD2016) [19].
GBD2016 is to be considered today as the driving light
on confirming, through epidemiology and disability
parameters, that MO(H) is only a sequela of CM and
must be summed in this clinical context adding a stron-
ger value to migraine itself, now ranked second place,
behind the low back pain only [20].
Therefore, the treatment for CM, now based on the
use of OnabotulinumtoxinA, should include the man-
agement of its sequela, making suddenly drop all the
puzzles arisen after the registration studies, in which 2/3
of enrolled CM patients had a co-diagnosis of MOH.
Such uncertainties have fallen with the following real-
world studies with OnabotulinumtoxinA for CM where
all treated patients were suffering from MO. The drug
efficacy contextually reduced, and it couldn’t be other-
wise, headache days and consequently the excessive
intake of medication.
The necessity of a definitive redefinition of this clinical
situation of Chronic Migraine plus Medication Overuse
[4] overwhelmingly arises. Figure 1 pieces together these
clinical evidences.
We could shortly witness a new pharmacological era
based on the use, in migraine treatment, of monoclonal
antibodies against Calcitonin-Gene-Related-Peptide or
its receptors, that if properly used in intercepting the
evolution from high-frequency migraine towards its
chronic phase will be able to reduce, in a decade, CM
and its complication, MO [21].
Another matter recently opened on the solidness of
the wall that supports the definition of chronic
migraine, the 15 days per month of migraine, seems
to waver on the basis of the brilliant study winner of
the 2017 Greppi Award: the natural fluctuation above
and below this barrier strongly challenge the concep-
tual modality of defining a form of migraine as
chronic [22].
Getting to the bottom of MO through
personalized medicine
We think today that MO originates from a numeric cal-
culation and this causes overuse in a quasi-mysterious
way. This cannot be all true. In fact, migraine experts
prescribe acute and preventative therapies to mitigate
pain and the symptomatology of existing comorbidities
[23]. Real world setting migraine patients might also
have other pathologies, not comorbid with migraine, that
require additional therapies. This complex treatment
may lead to many drug-drug interactions (DDIs), risking
to develop not only Adverse Events (AEs) but also to
reduce the clinical efficacy of the administered drug.
This is particularly true in the case of migraine acute
drugs leading to MO [24]. Genotype and phenotype also
have an influence in the development of DDIs, therefore
knowing them is crucial in choosing the best acute/pre-
ventative treatment and the appropriate drug interac-
tions. The DrugBank, SuperCyp, PharmaGkb [23] are
data banks containing all the potential genotype-
phenotype correlations in which it is possible to observe
all the acknowledged DDIs and, knowing these, to rec-
ommend a tailored treatment avoiding metabolic
clashes: in fact, more than 70% of prescribed drugs com-
pete for the same metabolic pathway, the superfamily of
cytochrome CYP450, and this represents the most com-
mon cause of drug reduction of efficacy and/or toxicity
(Fig. 2). By avoiding this cross-competition we will be
able to control this reduction of efficacy or drug toxicity
and, therefore, the risk of MO. The Personalized Medi-
cine model is particularly valid in migraine, where there
is special need for multiple therapies due to the high
number of comorbidities [25, 26]. With this clinic-
molecular-biology-based approach, we will be able to
obtain the better therapeutic performance, avoid DDIs,
and practically combine acute, preventative and comor-
bidities treatments as well as additional sided therapies
[26, 27]. Personalized Medicine is the future for safe
migraine treatment.
Final re-reading
Migraine is the second burdensome illness, if consid-
ered in terms of prevalence and disability. Its devel-
opment in chronicity highlights important personal,
organizational and health care problems. The
Fig. 1 Putative overlapping of Chronic Migraine, Medication Overuse
and Migraine Comorbidities
Martelletti The Journal of Headache and Pain  (2018) 19:2 Page 2 of 3
distinction between CM and MOH has created cul-
tural barriers in the management and rehabilitation.
The natural fluctuations of headache days challenge
the intrinsic definition of CM as we know it, and this
clashes with the concept that migraine is a solidly
progressive disorder. It is then necessary to bring
MOH back to the simple definition of CM complica-
tion, where various genetic factors yet to be defined
in large scales, multiple comorbidity factors and inad-
equate lifestyles might explain its development, and
to re-read the CM core. The possibility in a near
future to intercept migraine evolution from high fre-
quency onward through the new pharmacological
class of the monoclonal antibodies towards
Calcitonin-Gene-Related-Peptide or its receptors
might reduce its progression towards its fearsome
complication, medication overuse.
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Fig. 2 Drug-drug interactions between preventative and acute
migraine medications. The reported classes of drugs compete for
the same metabolic pathway, and this represents the most common
causes of drug reduction of efficacy and/or toxicity (for details
please refer to ref. [23], specifically to tables 1 and 2), leading to
medication overuse. Legenda AINS: anti-inflammatory non-steroidal
drugs; CYP450: cytochromes P450 (accounting for the metabolism of
more than 70% of prescribed drugs); MAOA: monoaminoxidase-A
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